Chemotherapy-Related Cognitive Dysfunction in Breast Cancer Survivors: A Systematic Review

Katherine Jinghua Lin; Cecile Lengacher; Carmen Rodriguez; Laura Szalacha; Jennifer Wolgemuth

doi:doi:10.11648/j.jctr.20210902.12

| Peer-Reviewed

Chemotherapy-Related Cognitive Dysfunction in Breast Cancer Survivors: A Systematic Review

Katherine Jinghua Lin, Cecile Lengacher, Carmen Rodriguez, Laura Szalacha, Jennifer Wolgemuth

Published in Journal of Cancer Treatment and Research (Volume 9, Issue 2)

Received: 25 May 2021 Accepted: 11 June 2021 Published: 21 June 2021

Views: Downloads:

Download PDF

Share This Article

Twitter
Linked In
Facebook

Abstract

Objectives: The major aims of this integrative review were to identify: 1) specific cognitive domains affected by chemotherapy; 2) predictors of cognitive dysfunction related to chemotherapy; 3) reported underlying mechanisms of chemotherapy-related cognitive dysfunction, and 4) clinical and research implications of chemotherapy-related cognitive dysfunction (CRCD) among breast cancer survivors. Methods: A computerized search of published research articles through the health journal databases of PubMed, CINAHL, EMBASE, and Web of Science was performed by using the keywords "chemotherapy," "cognitive dysfunction," "cognitive impairment," "cognitive decline," "breast cancer," and "breast carcinoma." References were screened according to inclusion and exclusion criteria. Results: After screening the titles and abstracts of 639 articles, 20 research studies were identified that focused on chemotherapy-related cognitive dysfunction in breast cancer for the final analysis. The 20 studies included: one longitudinal study, eleven prospective studies, two case-control studies, two retrospective studies, and four cross-sectional studies. The analysis of these 20 research studies contributed new knowledge about cognitive domains being affected by chemotherapy, risk factors for CRCD and underlying mechanisms of CRCD. Conclusion: This systematic review indicates significant clinical implications of early assessment and early interventions for CRCD to assist breast cancer survivors.

Published in	Journal of Cancer Treatment and Research (Volume 9, Issue 2)
DOI	10.11648/j.jctr.20210902.12
Page(s)	27-44
Creative Commons	This is an Open Access article, distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution and reproduction in any medium or format, provided the original work is properly cited.
Copyright	Copyright © The Author(s), 2021. Published by Science Publishing Group

Keywords

Chemotherapy, Cognitive Dysfunction, Breast Cancer

References

[1]	Statistics, U. S. B. C. 2020; Available from: https://www.breastcancer.org.
[2]	Breastcancer.org. Chemotherapy. 2019 [cited 2020 March 20]; Available from: https://www.breastcancer.org.
[3]	Cancer.org. Breast Cancer Facts & Figures 2019-2020. 2019 [cited 2020 March 20]; Available from: https://www.cancer.org.
[4]	Rodriguez Martin, B., et al., Study of Chemotherapy-Induced Cognitive Impairment in Women with Breast Cancer. Int J Environ Res Public Health, 2020. 17 (23).
[5]	Wefel, J. S., et al., International Cognition and Cancer Task Force recommendations to harmonise studies of cognitive function in patients with cancer. Lancet Oncol, 2011. 12 (7): p. 703-8.
[6]	Ganz, P. A., "Doctor, will the treatment you are recommending cause chemobrain?". J Clin Oncol, 2012. 30 (3): p. 229-31.
[7]	Pullens, M. J., J. De Vries, and J. A. Roukema, Subjective cognitive dysfunction in breast cancer patients: a systematic review. Psychooncology, 2010. 19 (11): p. 1127-38.
[8]	Vardy, J., Cognitive function in breast cancer survivors. Cancer Treat Res, 2009. 151: p. 387-419.
[9]	Yamada, T. H., et al., Neuropsychological outcomes of older breast cancer survivors: cognitive features ten or more years after chemotherapy. J Neuropsychiatry Clin Neurosci, 2010. 22 (1): p. 48-54.
[10]	Jim, H. S., et al., Cognitive functioning in breast cancer survivors: a controlled comparison. Cancer, 2009. 115 (8): p. 1776-83.
[11]	Jim, H. S., et al., Meta-analysis of cognitive functioning in breast cancer survivors previously treated with standard-dose chemotherapy. J Clin Oncol, 2012. 30 (29): p. 3578-87.
[12]	Wefel, J. S., et al., Acute and late onset cognitive dysfunction associated with chemotherapy in women with breast cancer. Cancer, 2010. 116 (14): p. 3348-56.
[13]	Xuan, H., et al., Altered network efficiency of functional brain networks in patients with breast cancer after chemotherapy. Oncotarget, 2017. 8 (62): p. 105648-105661.
[14]	Argyriou, A. A., et al., Either called "chemobrain" or "chemofog," the long-term chemotherapy-induced cognitive decline in cancer survivors is real. J Pain Symptom Manage, 2011. 41 (1): p. 126-39.
[15]	Klemp, J. R., et al., Cognitive functioning and quality of life following chemotherapy in pre- and peri-menopausal women with breast cancer. Support Care Cancer, 2018. 26 (2): p. 575-583.
[16]	Ng, T., et al., Evaluation of plasma brain-derived neurotrophic factor levels and self-perceived cognitive impairment post-chemotherapy: a longitudinal study. BMC Cancer, 2017. 17 (1): p. 867.
[17]	Kesler, S. R. and D. W. Blayney, Neurotoxic Effects of Anthracycline- vs Nonanthracycline-Based Chemotherapy on Cognition in Breast Cancer Survivors. JAMA Oncol, 2016. 2 (2): p. 185-92.
[18]	Murata, K., et al., [Idiopathic thrombocytopenic purpura during chemotherapy for liver metastasis of rectal cancer]. Gan To Kagaku Ryoho, 2010. 37 (12): p. 2605-7.
[19]	Vardy, J. L., et al., A mechanistic cohort study evaluating cognitive impairment in women treated for breast cancer. Brain Imaging Behav, 2017. (Please Delete this One)
[20]	Miao, H., et al., Functional connectivity change of brain default mode network in breast cancer patients after chemotherapy. Neuroradiology, 2016. 58 (9): p. 921-8.
[21]	Thomas, B. H., et al., A process for systematically reviewing the literature: providing the research evidence for public health nursing interventions. Worldviews Evid Based Nurs, 2004. 1 (3): p. 176-84.
[22]	Biglia, N., et al., Objective and self-reported cognitive dysfunction in breast cancer women treated with chemotherapy: a prospective study. Eur J Cancer Care (Engl), 2012. 21 (4): p. 485-92.
[23]	Cerulla, N., et al., Role of taxanes in chemotherapy-related cognitive impairment: A prospective longitudinal study. Breast Cancer Res Treat, 2017. 164 (1): p. 179-187.
[24]	Jung, M. S., et al., Cognitive dysfunction and symptom burden in women treated for breast cancer: a prospective behavioral and fMRI analysis. Brain Imaging Behav, 2017. 11 (1): p. 86-97.
[25]	Menning, S., et al., Cognitive Impairment in a Subset of Breast Cancer Patients After Systemic Therapy-Results From a Longitudinal Study. J Pain Symptom Manage, 2016. 52 (4): p. 560-569 e1.
[26]	Piccirillo, J. F., et al., Cognitive impairment after chemotherapy related to atypical network architecture for executive control. Oncology, 2015. 88 (6): p. 360-8.
[27]	Ramalho, M., et al., Cognitive impairment in the first year after breast cancer diagnosis: A prospective cohort study. Breast, 2017. 32: p. 173-178.
[28]	Ahles, T. A., et al., Longitudinal assessment of cognitive changes associated with adjuvant treatment for breast cancer: impact of age and cognitive reserve. J Clin Oncol, 2010. 28 (29): p. 4434-40.
[29]	Jansen, C. E., et al., A prospective longitudinal study of chemotherapy-induced cognitive changes in breast cancer patients. Support Care Cancer, 2011. 19 (10): p. 1647-56.
[30]	Quesnel, C., J. Savard, and H. Ivers, Cognitive impairments associated with breast cancer treatments: results from a longitudinal study. Breast Cancer Res Treat, 2009. 116 (1): p. 113-23.
[31]	Tao, L., et al., Impairment of the executive function in breast cancer patients receiving chemotherapy treatment: a functional MRI study. Eur J Cancer Care (Engl), 2017. 26 (6).
[32]	Bower, J. E., et al., Cytokine genetic variations and fatigue among patients with breast cancer. J Clin Oncol, 2013. 31 (13): p. 1656-61.
[33]	Deprez, S., et al., Longitudinal assessment of chemotherapy-induced structural changes in cerebral white matter and its correlation with impaired cognitive functioning. J Clin Oncol, 2012. 30 (3): p. 274-81.
[34]	Kesler, S., et al., Reduced hippocampal volume and verbal memory performance associated with interleukin-6 and tumor necrosis factor-alpha levels in chemotherapy-treated breast cancer survivors. Brain Behav Immun, 2013. 30 Suppl: p. S109-16.
[35]	Quality assessment tool for quantitative studies.. 2008, Hamilton, ON: National Collaborating Centre for Methods and Tools.
[36]	Jansen, C. E., et al., A metaanalysis of studies of the effects of cancer chemotherapy on various domains of cognitive function. Cancer, 2005. 104 (10): p. 2222-33.
[37]	Maass, S. W., et al., The prevalence of long-term symptoms of depression and anxiety after breast cancer treatment: A systematic review. Maturitas, 2015. 82 (1): p. 100-8.
[38]	Gass, C. S. and R. E. Curiel, Test anxiety in relation to measures of cognitive and intellectual functioning. Arch Clin Neuropsychol, 2011. 26 (5): p. 396-404.
[39]	Hermelink, K., et al., Elucidating pretreatment cognitive impairment in breast cancer patients: the impact of cancer-related post-traumatic stress. J Natl Cancer Inst, 2015. 107 (7).
[40]	Vardy, J. L., et al., A mechanistic cohort study evaluating cognitive impairment in women treated for breast cancer. Brain Imaging Behav, 2017. 13 (1): p. 15-26. (Keep this one).
[41]	Deprez, S., et al., Chemotherapy-induced structural changes in cerebral white matter and its correlation with impaired cognitive functioning in breast cancer patients. Hum Brain Mapp, 2011. 32 (3): p. 480-93.
[42]	De Ruiter, M. B., et al., Late effects of high-dose adjuvant chemotherapy on white and gray matter in breast cancer survivors: converging results from multimodal magnetic resonance imaging. Hum Brain Mapp, 2012. 33 (12): p. 2971-83.
[43]	Askren, M. K., et al., Neuromarkers of fatigue and cognitive complaints following chemotherapy for breast cancer: a prospective fMRI investigation. Breast Cancer Res Treat, 2014. 147 (2): p. 445-55.
[44]	Janelsins, M. C., et al., Prevalence, mechanisms, and management of cancer-related cognitive impairment. Int Rev Psychiatry, 2014. 26 (1): p. 102-13.
[45]	Pendergrass, J. C., S. D. Targum, and J. E. Harrison, Cognitive Impairment Associated with Cancer: A Brief Review. Innov Clin Neurosci, 2018. 15 (1-2): p. 36-44.
[46]	Wefel, J. S., et al., Clinical characteristics, pathophysiology, and management of noncentral nervous system cancer-related cognitive impairment in adults. CA Cancer J Clin, 2015. 65 (2): p. 123-38.
[47]	Allen, B. J., S. A. Reid-Arndt, and T. Rolan, Neuropsychological functioning in a young adult case of schizencephaly. Clin Neuropsychol, 2010. 24 (5): p. 827-40.
[48]	Hutchinson, A. D., et al., Objective and subjective cognitive impairment following chemotherapy for cancer: a systematic review. Cancer Treat Rev, 2012. 38 (7): p. 926-34.
[49]	Collins, B., et al., Cognitive effects of chemotherapy in breast cancer patients: a dose-response study. Psychooncology, 2013. 22 (7): p. 1517-27.
[50]	Seigers, R. and J. E. Fardell, Neurobiological basis of chemotherapy-induced cognitive impairment: a review of rodent research. Neurosci Biobehav Rev, 2011. 35 (3): p. 729-41.
[51]	Binnewijzend, M. A., et al., Resting-state fMRI changes in Alzheimer's disease and mild cognitive impairment. Neurobiol Aging, 2012. 33 (9): p. 2018-28.
[52]	McDonald, B. C., et al., Alterations in brain activation during working memory processing associated with breast cancer and treatment: a prospective functional magnetic resonance imaging study. J Clin Oncol, 2012. 30 (20): p. 2500-8.
[53]	Mordente, A., et al., Anthracyclines and mitochondria. Adv Exp Med Biol, 2012. 942: p. 385-419.
[54]	Sanoff, H. K., et al., Effect of cytotoxic chemotherapy on markers of molecular age in patients with breast cancer. J Natl Cancer Inst, 2014. 106 (4): p. dju057.
[55]	Joshi, G., et al., Alterations in brain antioxidant enzymes and redox proteomic identification of oxidized brain proteins induced by the anti-cancer drug adriamycin: implications for oxidative stress-mediated chemobrain. Neuroscience, 2010. 166 (3): p. 796-807.
[56]	Niedzielska, E., et al., Oxidative Stress in Neurodegenerative Diseases. Mol Neurobiol, 2016. 53 (6): p. 4094-4125.
[57]	Janelsins, M. C., et al., Differential expression of cytokines in breast cancer patients receiving different chemotherapies: implications for cognitive impairment research. Support Care Cancer, 2012. 20 (4): p. 831-9.
[58]	Ahles, T. A. and A. J. Saykin, Candidate mechanisms for chemotherapy-induced cognitive changes. Nat Rev Cancer, 2007. 7 (3): p. 192-201.
[59]	Ando-Tanabe, N., et al., Cognitive function in women with breast cancer receiving adjuvant chemotherapy and healthy controls. Breast Cancer, 2014. 21 (4): p. 453-62.
[60]	Berman, M. G., et al., Pretreatment worry and neurocognitive responses in women with breast cancer. Health Psychol, 2014. 33 (3): p. 222-31.
[61]	Anticevic, A., et al., The role of default network deactivation in cognition and disease. Trends Cogn Sci, 2012. 16 (12): p. 584-92.
[62]	Sleight, A., Coping with cancer-related cognitive dysfunction: a scoping review of the literature. Disabil Rehabil, 2016. 38 (4): p. 400-8.
[63]	Ferguson, R. J., et al., Development of CBT for chemotherapy-related cognitive change: results of a waitlist control trial. Psychooncology, 2012. 21 (2): p. 176-86.
[64]	Wolf, T. J., et al., The Feasibility of Using Metacognitive Strategy Training to Improve Cognitive Performance and Neural Connectivity in Women with Chemotherapy-Induced Cognitive Impairment. Oncology, 2016. 91 (3): p. 143-52.
[65]	Milbury, K., et al., Tibetan sound meditation for cognitive dysfunction: results of a randomized controlled pilot trial. Psychooncology, 2013. 22 (10): p. 2354-63.
[66]	Lengacher, C. A., et al., Mindfulness based stress reduction in post-treatment breast cancer patients: an examination of symptoms and symptom clusters. J Behav Med, 2012. 35 (1): p. 86-94.
[67]	Lengacher, C. A., et al., Moderating Effects of Genetic Polymorphisms on Improvements in Cognitive Impairment in Breast Cancer Survivors Participating in a 6-Week Mindfulness-Based Stress Reduction Program. Biol Res Nurs, 2015. 17 (4): p. 393-404.
[68]	Morean, D. F., L. O' Dwyer, and L. R. Cherney, Therapies for Cognitive Deficits Associated With Chemotherapy for Breast Cancer: A Systematic Review of Objective Outcomes. Arch Phys Med Rehabil, 2015. 96 (10): p. 1880-97.

Cite This Article

Plain Text BibTeX RIS

APA Style

Katherine Jinghua Lin, Cecile Lengacher, Carmen Rodriguez, Laura Szalacha, Jennifer Wolgemuth. (2021). Chemotherapy-Related Cognitive Dysfunction in Breast Cancer Survivors: A Systematic Review. Journal of Cancer Treatment and Research, 9(2), 27-44. https://doi.org/10.11648/j.jctr.20210902.12

Copy | Download

ACS Style

Katherine Jinghua Lin; Cecile Lengacher; Carmen Rodriguez; Laura Szalacha; Jennifer Wolgemuth. Chemotherapy-Related Cognitive Dysfunction in Breast Cancer Survivors: A Systematic Review. J. Cancer Treat. Res. 2021, 9(2), 27-44. doi: 10.11648/j.jctr.20210902.12

Copy | Download

AMA Style

Katherine Jinghua Lin, Cecile Lengacher, Carmen Rodriguez, Laura Szalacha, Jennifer Wolgemuth. Chemotherapy-Related Cognitive Dysfunction in Breast Cancer Survivors: A Systematic Review. J Cancer Treat Res. 2021;9(2):27-44. doi: 10.11648/j.jctr.20210902.12

Copy | Download

@article{10.11648/j.jctr.20210902.12,
  author = {Katherine Jinghua Lin and Cecile Lengacher and Carmen Rodriguez and Laura Szalacha and Jennifer Wolgemuth},
  title = {Chemotherapy-Related Cognitive Dysfunction in Breast Cancer Survivors: A Systematic Review},
  journal = {Journal of Cancer Treatment and Research},
  volume = {9},
  number = {2},
  pages = {27-44},
  doi = {10.11648/j.jctr.20210902.12},
  url = {https://doi.org/10.11648/j.jctr.20210902.12},
  eprint = {https://article.sciencepublishinggroup.com/pdf/10.11648.j.jctr.20210902.12},
  abstract = {Objectives: The major aims of this integrative review were to identify: 1) specific cognitive domains affected by chemotherapy; 2) predictors of cognitive dysfunction related to chemotherapy; 3) reported underlying mechanisms of chemotherapy-related cognitive dysfunction, and 4) clinical and research implications of chemotherapy-related cognitive dysfunction (CRCD) among breast cancer survivors. Methods: A computerized search of published research articles through the health journal databases of PubMed, CINAHL, EMBASE, and Web of Science was performed by using the keywords "chemotherapy," "cognitive dysfunction," "cognitive impairment," "cognitive decline," "breast cancer," and "breast carcinoma." References were screened according to inclusion and exclusion criteria. Results: After screening the titles and abstracts of 639 articles, 20 research studies were identified that focused on chemotherapy-related cognitive dysfunction in breast cancer for the final analysis. The 20 studies included: one longitudinal study, eleven prospective studies, two case-control studies, two retrospective studies, and four cross-sectional studies. The analysis of these 20 research studies contributed new knowledge about cognitive domains being affected by chemotherapy, risk factors for CRCD and underlying mechanisms of CRCD. Conclusion: This systematic review indicates significant clinical implications of early assessment and early interventions for CRCD to assist breast cancer survivors.},
 year = {2021}
}

Copy | Download

TY  - JOUR
T1  - Chemotherapy-Related Cognitive Dysfunction in Breast Cancer Survivors: A Systematic Review
AU  - Katherine Jinghua Lin
AU  - Cecile Lengacher
AU  - Carmen Rodriguez
AU  - Laura Szalacha
AU  - Jennifer Wolgemuth
Y1  - 2021/06/21
PY  - 2021
N1  - https://doi.org/10.11648/j.jctr.20210902.12
DO  - 10.11648/j.jctr.20210902.12
T2  - Journal of Cancer Treatment and Research
JF  - Journal of Cancer Treatment and Research
JO  - Journal of Cancer Treatment and Research
SP  - 27
EP  - 44
PB  - Science Publishing Group
SN  - 2376-7790
UR  - https://doi.org/10.11648/j.jctr.20210902.12
AB  - Objectives: The major aims of this integrative review were to identify: 1) specific cognitive domains affected by chemotherapy; 2) predictors of cognitive dysfunction related to chemotherapy; 3) reported underlying mechanisms of chemotherapy-related cognitive dysfunction, and 4) clinical and research implications of chemotherapy-related cognitive dysfunction (CRCD) among breast cancer survivors. Methods: A computerized search of published research articles through the health journal databases of PubMed, CINAHL, EMBASE, and Web of Science was performed by using the keywords "chemotherapy," "cognitive dysfunction," "cognitive impairment," "cognitive decline," "breast cancer," and "breast carcinoma." References were screened according to inclusion and exclusion criteria. Results: After screening the titles and abstracts of 639 articles, 20 research studies were identified that focused on chemotherapy-related cognitive dysfunction in breast cancer for the final analysis. The 20 studies included: one longitudinal study, eleven prospective studies, two case-control studies, two retrospective studies, and four cross-sectional studies. The analysis of these 20 research studies contributed new knowledge about cognitive domains being affected by chemotherapy, risk factors for CRCD and underlying mechanisms of CRCD. Conclusion: This systematic review indicates significant clinical implications of early assessment and early interventions for CRCD to assist breast cancer survivors.
VL  - 9
IS  - 2
ER  -

Copy | Download

Author Information

Katherine Jinghua Lin

College of Nursing, College of Education, University of South Florida, Tampa, USA
Cecile Lengacher

College of Nursing, College of Education, University of South Florida, Tampa, USA
Carmen Rodriguez

College of Nursing, College of Education, University of South Florida, Tampa, USA
Laura Szalacha

College of Nursing, College of Education, University of South Florida, Tampa, USA
Jennifer Wolgemuth

College of Nursing, College of Education, University of South Florida, Tampa, USA

Download PDF

Sections

Plain Text BibTeX RIS

APA Style

Katherine Jinghua Lin, Cecile Lengacher, Carmen Rodriguez, Laura Szalacha, Jennifer Wolgemuth. (2021). Chemotherapy-Related Cognitive Dysfunction in Breast Cancer Survivors: A Systematic Review. Journal of Cancer Treatment and Research, 9(2), 27-44. https://doi.org/10.11648/j.jctr.20210902.12

Copy | Download

ACS Style

Katherine Jinghua Lin; Cecile Lengacher; Carmen Rodriguez; Laura Szalacha; Jennifer Wolgemuth. Chemotherapy-Related Cognitive Dysfunction in Breast Cancer Survivors: A Systematic Review. J. Cancer Treat. Res. 2021, 9(2), 27-44. doi: 10.11648/j.jctr.20210902.12

Copy | Download

AMA Style

Katherine Jinghua Lin, Cecile Lengacher, Carmen Rodriguez, Laura Szalacha, Jennifer Wolgemuth. Chemotherapy-Related Cognitive Dysfunction in Breast Cancer Survivors: A Systematic Review. J Cancer Treat Res. 2021;9(2):27-44. doi: 10.11648/j.jctr.20210902.12

Copy | Download

@article{10.11648/j.jctr.20210902.12,
  author = {Katherine Jinghua Lin and Cecile Lengacher and Carmen Rodriguez and Laura Szalacha and Jennifer Wolgemuth},
  title = {Chemotherapy-Related Cognitive Dysfunction in Breast Cancer Survivors: A Systematic Review},
  journal = {Journal of Cancer Treatment and Research},
  volume = {9},
  number = {2},
  pages = {27-44},
  doi = {10.11648/j.jctr.20210902.12},
  url = {https://doi.org/10.11648/j.jctr.20210902.12},
  eprint = {https://article.sciencepublishinggroup.com/pdf/10.11648.j.jctr.20210902.12},
  abstract = {Objectives: The major aims of this integrative review were to identify: 1) specific cognitive domains affected by chemotherapy; 2) predictors of cognitive dysfunction related to chemotherapy; 3) reported underlying mechanisms of chemotherapy-related cognitive dysfunction, and 4) clinical and research implications of chemotherapy-related cognitive dysfunction (CRCD) among breast cancer survivors. Methods: A computerized search of published research articles through the health journal databases of PubMed, CINAHL, EMBASE, and Web of Science was performed by using the keywords "chemotherapy," "cognitive dysfunction," "cognitive impairment," "cognitive decline," "breast cancer," and "breast carcinoma." References were screened according to inclusion and exclusion criteria. Results: After screening the titles and abstracts of 639 articles, 20 research studies were identified that focused on chemotherapy-related cognitive dysfunction in breast cancer for the final analysis. The 20 studies included: one longitudinal study, eleven prospective studies, two case-control studies, two retrospective studies, and four cross-sectional studies. The analysis of these 20 research studies contributed new knowledge about cognitive domains being affected by chemotherapy, risk factors for CRCD and underlying mechanisms of CRCD. Conclusion: This systematic review indicates significant clinical implications of early assessment and early interventions for CRCD to assist breast cancer survivors.},
 year = {2021}
}

Copy | Download

TY  - JOUR
T1  - Chemotherapy-Related Cognitive Dysfunction in Breast Cancer Survivors: A Systematic Review
AU  - Katherine Jinghua Lin
AU  - Cecile Lengacher
AU  - Carmen Rodriguez
AU  - Laura Szalacha
AU  - Jennifer Wolgemuth
Y1  - 2021/06/21
PY  - 2021
N1  - https://doi.org/10.11648/j.jctr.20210902.12
DO  - 10.11648/j.jctr.20210902.12
T2  - Journal of Cancer Treatment and Research
JF  - Journal of Cancer Treatment and Research
JO  - Journal of Cancer Treatment and Research
SP  - 27
EP  - 44
PB  - Science Publishing Group
SN  - 2376-7790
UR  - https://doi.org/10.11648/j.jctr.20210902.12
AB  - Objectives: The major aims of this integrative review were to identify: 1) specific cognitive domains affected by chemotherapy; 2) predictors of cognitive dysfunction related to chemotherapy; 3) reported underlying mechanisms of chemotherapy-related cognitive dysfunction, and 4) clinical and research implications of chemotherapy-related cognitive dysfunction (CRCD) among breast cancer survivors. Methods: A computerized search of published research articles through the health journal databases of PubMed, CINAHL, EMBASE, and Web of Science was performed by using the keywords "chemotherapy," "cognitive dysfunction," "cognitive impairment," "cognitive decline," "breast cancer," and "breast carcinoma." References were screened according to inclusion and exclusion criteria. Results: After screening the titles and abstracts of 639 articles, 20 research studies were identified that focused on chemotherapy-related cognitive dysfunction in breast cancer for the final analysis. The 20 studies included: one longitudinal study, eleven prospective studies, two case-control studies, two retrospective studies, and four cross-sectional studies. The analysis of these 20 research studies contributed new knowledge about cognitive domains being affected by chemotherapy, risk factors for CRCD and underlying mechanisms of CRCD. Conclusion: This systematic review indicates significant clinical implications of early assessment and early interventions for CRCD to assist breast cancer survivors.
VL  - 9
IS  - 2
ER  -

Copy | Download